Abstracts tagged "Disparities"

Abstract Number: 0190 • ACR Convergence 2023
Racial Disparities in Self-reported Extent and Reasons for Nonadherence in SLE
Kai Sun¹, Londyn Robinson², Amanda Eudy³, Jennifer Rogers¹, Rebecca Sadun¹, Lisa Criscione-Schreiber⁴, Jayanth Doss¹ and Megan Clowse⁵, ¹Duke University, Durham, NC, ²University of Minnesota Medical School, Minneapolis, MN, ³Duke University, Raleigh, NC, ⁴Duke University School of Medicine, Durham, NC, ⁵Duke University, Chapel Hill, NC
Background/Purpose: Medication nonadherence is common in SLE and disproportionately affects Black patients. Nonadherence leads to increased hospitalizations, morbidity, and mortality and is a modifiable factor…
Abstract Number: 1021 • ACR Convergence 2023
Racial Disparities Between Black and White Patients in Joint Replacement Surgery: A Systematic Review
Max Krall¹, Samuel Good¹, Collin Brantner², Diyu Pearce-Fisher², Susan Goodman², Michael Parks², Peter Sculco², Cynthia Kahlenberg², Ajay Premkumar², Michelle Demetres³ and John FitzGerald¹, ¹University of California Los Angeles, Los Angeles, CA, ²Hospital for Special Surgery, New York, NY, ³Weill Cornell Medicine, New York, NY
Background/Purpose: Despite the documented efficacy of joint replacement surgery (JRS) for the management of refractory hip or knee osteoarthritis (OA), multiple studies have documented lower…
Abstract Number: 1684 • ACR Convergence 2023
The Impact of Pregnancy Timing on Outcomes in SLE
Catherine Sims¹, Amanda Eudy², Ceshae Harding¹, Cuoghi Edens³, Mehret Birru Talabi⁴, Rosalind Ramsey-Goldman⁵, Laura Neil¹ and Megan Clowse⁶, ¹Duke University, Durham, NC, ²Duke University, Raleigh, NC, ³University of Chicago, Chicago, IL, ⁴University of Pittsburgh, Pittsburgh, PA, ⁵Northwestern University, Chicago, IL, ⁶Duke University, Chapel Hill, NC
Background/Purpose: To minimize risk of poor pregnancy outcomes, the ACR Reproductive Health Guideline recommends women conceive when SLE is well controlled and treated with pregnancy-compatible…
Abstract Number: 0191 • ACR Convergence 2023
Reproductive Health Discussions Between Rheumatology Providers and Systemic Lupus Erythematosus Patients: A Survey of English and Spanish-Speaking Patients
Meredith Xepoleas¹, Martha Delgado², Jack Rodman³, Julia Simard⁴, Sandy Lee⁵ and Leanna Wise⁶, ¹Keck School of Medicine of University of Southern California, Los Angeles, CA, ²LAC+USC/Keck School of Medicine, Los Angeles, CA, ³University of Southern California, Los Angeles, CA, ⁴Department of Epidemiology & Population Health, Stanford University School of Medicine, Stanford, CA, ⁵University of Southern California, Walnut, CA, ⁶LAC+USC/Keck Medicine of USC, Pasadena, CA
Background/Purpose: Systemic lupus erythematosus (SLE) primarily affects women of childbearing age, with a higher burden in non-Caucasian populations. Due to the increased risk of adverse…
Abstract Number: 1022 • ACR Convergence 2023
Lower Rates of Statin Therapy Initiation in Dermatomyositis/Polymyositis vs. Rheumatoid Arthritis Patients with Hyperlipidemia: A Multicenter USA-Based Study (2018-2023)
Joseph Fares¹, ross Summer¹ and Giorgos Loizidis², ¹The Jane and Leonard Korman Respiratory Institute, Thomas Jefferson University Hospital, Philadelphia, PA, ²Division of Rheumatology, Thomas Jefferson University Hospital, Philadelphia, PA
Background/Purpose: Despite the proven cardioprotective benefits of statin therapy in RA, concern for statin-associated muscle symptoms (SAMS) might deter clinicians from prescribing them to DM/PM…
Abstract Number: 1817 • ACR Convergence 2023
Geographic Variability of Inflammatory Bowel Disease Related Mortality, 1999-2019; CDC WONDER
Saleha Aziz¹, Anum Akhlaq¹, Sana Gurz² and Yousaf Zafar¹, ¹University of Mississippi Medical Center, Jackson, MS, ²University of Nevada, Las Vegas, NV
Background/Purpose: The United States makes a significant contribution to Inflammatory Bowel Disease (IBD) related disease burden worldwide. However, data on geographic variability of IBD related…
Abstract Number: 0194 • ACR Convergence 2023
Reproductive Health Conversations with a Primarily Hispanic Systemic Lupus Erythematosus Population: Influences and Barriers
Zarmeen Zaheer¹, Martha Delgado², Jack Rodman³, Julia Simard⁴, Sandy Lee⁵ and Leanna Wise⁶, ¹Huntington Health, Tampa, FL, ²LAC+USC/Keck School of Medicine, Los Angeles, CA, ³University of Southern California, Los Angeles, CA, ⁴Department of Epidemiology & Population Health, Stanford University School of Medicine, Stanford, CA, ⁵University of Southern California, Walnut, CA, ⁶LAC+USC/Keck Medicine of USC, Pasadena, CA
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease most commonly seen in women of childbearing age, with a greater burden in non-Caucasian populations. The…
Abstract Number: 1024 • ACR Convergence 2023
Relationship Between Race and Ethnicity, Time to Diagnosis, and Disease Activity for Children with Juvenile Idiopathic Arthritis in the CARRA Registry
Sarah McGuire¹, Tania Atanassova², Joanna Madej², Manuel Jimenez², Daniel Horton¹ and for the CARRA TMJ Arthritis Workgroup³, ¹Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ²Rutgers, Robert Wood Johnson Medical School, New Brunswick, NJ, ³Childhood Arthritis and Rheumatology Research Alliance, Washington, DC
Background/Purpose: Compared to non-Hispanic White children, Black children diagnosed with juvenile idiopathic arthritis (JIA) have more severe disease at diagnosis and worse outcomes, such as…
Abstract Number: 1841 • ACR Convergence 2023
Clinical Trial Perceptions Among Male Patients with Systemic Lupus Erythematosus (SLE): Georgians Organized Against Lupus (GOAL) Cohort
Hilton Mozee¹, Charmayne Dunlop-Thomas¹, Gaobin Bao¹, Kim Schofield², Jessica Williams³ and S. Sam Lim¹, ¹Emory University, Atlanta, GA, ²Georgia State Rep. HD 63, Atlanta, GA, ³Emory University School of Medicine, Atlanta, GA
Background/Purpose: Minority patients are disproportionately affected by SLE. Yet, they are underrepresented in SLE clinical trials compared to White patients. Specifically, patients that identify as…
Abstract Number: 0195 • ACR Convergence 2023
Assessing Cardiovascular Risk in Black and Latino Patients with Systemic Lupus Erythematosus
Glorielly Gonzalez¹, Zerai Manna², Alice Fike³, Jun Chu², sarfaraz Hasni² and Brian Dizon¹, ¹National Institute of Arthritis and Musculoskelatal and Skin Diseases, Bethesda, MD, ²Lupus Clinical Trials Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (NIH), Bethesda, MD, ³National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD
Background/Purpose: Cardiovascular disease (CVD) is a major cause of mortality among patients with systemic autoimmune disease. Patients with systemic lupus erythematosus (SLE) exhibit accelerated cardiovascular…
Abstract Number: 1025 • ACR Convergence 2023
Embedding Treat to Target Principles in Rheumatoid Arthritis Patient Education in Routine Care of Ethnic Minority Patients
Sharon Dowell¹, Mercedes Quinones², Tahereh Jamshidi³, Ilona Jileaeva⁴, Oshoze Kadiri⁴ and Gail Kerr⁵, ¹NEA Baptist Memorial Hospital, Jonesboro, AR, ²Washington DC VA Medical Center, Bethesda, MD, ³Howard University Hospital, Bethesda, MD, ⁴Howard University, Washington, DC, ⁵Washington DC VAMC/Georgetown and Howard Universities, Washington, DC
Background/Purpose: A successful treat to target (T2T) strategy in ethnic minority (EM) patients with rheumatoid arthritis (RA) could improve patient outcomes and help reduce healthcare…
Abstract Number: 1859 • ACR Convergence 2023
Examining Hydroxychloroquine Prescribing and SLE Damage in a Statewide Lupus Cohort
Jenna Cormier¹, Bryn Sutherland¹, Yiran Jiang², David Gazeley³, Jonathan Katz⁴, Shalvi Parikh⁴, Carlos Torres⁵, Eden Charles⁵, Ang Yu⁶, Felix Elwert⁶ and Christie M. Bartels⁷, ¹Medical College of Wisconsin, Milwaukee, WI, ²Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, ³Medical College of Wisconsin, Wauwatosa, WI, ⁴Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁵University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁶Department of Sociology, University of Wisconsin, Madison, WI, ⁷University of Wisconsin, School of Medicine and Public Health, Madison, WI
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous disease that disproportionately affects women, racially and ethnically minoritized populations, and people of lower socioeconomic status (SES).…
Abstract Number: 014 • 2023 Pediatric Rheumatology Symposium
Characterizing Lupus in African American Children in Southern United States
Anita Dhanrajani¹, Taylor Long¹, Spencer Hagwood², Leslie Johnson¹ and Cynthia Karlson¹, ¹University of Mississipi Medical Center, Jackson, MS, ²University of Mississipi Medical Center School of Medicine, Jackson, MS
Background/Purpose: African-American (AA) ethnicity is a known predisposing factor for childhood onset systemic lupus erythematosus (cSLE) and a predictor of poor outcomes. In addition to…
Abstract Number: 025 • 2023 Pediatric Rheumatology Symposium
Patient- and Center-level Risk Factors for Research Lost to Follow-up Using the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry
Monica Aswani, Livie Huie, Kristine Hearld, Melissa Mannion and Emily Smitherman, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Clinical registries are typically envisioned to be representative of a target patient population and reflective of health care delivery practices for said population. Variation…
Abstract Number: 085 • 2023 Pediatric Rheumatology Symposium
Identification of Barriers to Care Experienced by Children with Rheumatic Disease: A Qualitative Study
Olivia Kwan¹, Gloria Garcia², Kiana Johnson³, Melissa Oliver¹, Stacey Tarvin⁴, Alvaro Tori¹, Brandi Stevens¹ and Martha Rodriguez⁴, ¹Indiana University, Indianapolis, IN, ²Indiana University School of Medicine, Indianapolis, IN, ³East Tennessee State University, Johnson City, TN, ⁴Riley Hospital for Children at Indiana University Health, Indianapolis, IN
Background/Purpose: Pediatric rheumatic diseases are known to have disparities in disease outcomes, but many drivers of these inequities are unknown. Social determinants of health are…

« Previous Page
1
…
7
8
9
10
11
…
18
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.